Organogenesis (ORGO) Competitors $4.51 -0.11 (-2.38%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.51 +0.00 (+0.11%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. AMRX, IBRX, BHC, APLS, XENE, AGIO, BEAM, ARWR, TWST, and HRMYShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), Bausch Health Cos (BHC), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Agios Pharmaceuticals (AGIO), Beam Therapeutics (BEAM), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors Amneal Pharmaceuticals ImmunityBio Bausch Health Cos Apellis Pharmaceuticals Xenon Pharmaceuticals Agios Pharmaceuticals Beam Therapeutics Arrowhead Pharmaceuticals Twist Bioscience Harmony Biosciences Amneal Pharmaceuticals (NASDAQ:AMRX) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Which has higher earnings & valuation, AMRX or ORGO? Organogenesis has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.79B0.88-$116.89M-$0.04-195.75Organogenesis$482.04M1.19$860K-$0.17-26.53 Is AMRX or ORGO more profitable? Amneal Pharmaceuticals has a net margin of -0.46% compared to Organogenesis' net margin of -3.46%. Organogenesis' return on equity of -4.00% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-0.46% -188.26% 5.34% Organogenesis -3.46%-4.00%-2.26% Does the media refer more to AMRX or ORGO? In the previous week, Amneal Pharmaceuticals had 2 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Amneal Pharmaceuticals and 1 mentions for Organogenesis. Amneal Pharmaceuticals' average media sentiment score of 0.89 beat Organogenesis' score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, AMRX or ORGO? Amneal Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Do analysts rate AMRX or ORGO? Amneal Pharmaceuticals currently has a consensus price target of $11.60, suggesting a potential upside of 48.15%. Organogenesis has a consensus price target of $6.50, suggesting a potential upside of 44.12%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Organogenesis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals have more ownership in AMRX or ORGO? 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 26.6% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 33.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryAmneal Pharmaceuticals beats Organogenesis on 9 of the 16 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$586.06M$2.46B$5.48B$9.51BDividend YieldN/A1.81%4.73%4.08%P/E Ratio-26.538.9728.6723.80Price / Sales1.19437.63373.9066.65Price / Cash22.14157.7635.4557.96Price / Book2.164.838.275.55Net Income$860K$31.62M$3.24B$259.03M7 Day Performance-10.34%-5.28%-3.69%-4.59%1 Month Performance11.36%4.38%4.33%4.46%1 Year Performance69.55%-2.49%25.95%18.03% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.004 of 5 stars$4.51-2.4%$6.50+44.1%+62.2%$586.06M$482.04M-26.53950Upcoming EarningsAMRXAmneal Pharmaceuticals3.5296 of 5 stars$8.17+1.4%$11.60+42.0%+9.1%$2.53B$2.79B-204.208,100Positive NewsIBRXImmunityBio2.2348 of 5 stars$2.65-7.3%$12.25+362.3%-50.5%$2.52B$14.74M-4.57590News CoverageGap DownBHCBausch Health Cos4.6465 of 5 stars$6.88+1.6%$7.38+7.2%-6.4%$2.51B$9.63B-62.5520,700News CoverageEarnings ReportAnalyst UpgradeAPLSApellis Pharmaceuticals4.704 of 5 stars$18.75-4.3%$40.00+113.3%-36.3%$2.46B$781.37M-10.47770Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionXENEXenon Pharmaceuticals3.0402 of 5 stars$30.97+2.2%$54.82+77.0%-30.3%$2.33B$9.43M-9.59210News CoveragePositive NewsShort Interest ↑AGIOAgios Pharmaceuticals4.001 of 5 stars$37.20-7.0%$56.33+51.4%-21.3%$2.32B$36.50M3.31390News CoverageEarnings ReportBEAMBeam Therapeutics2.6035 of 5 stars$20.83-4.1%$48.75+134.0%-37.9%$2.18B$63.52M-4.52510Upcoming EarningsInsider TradeGap DownARWRArrowhead Pharmaceuticals3.8283 of 5 stars$16.20+2.9%$43.71+169.8%-42.0%$2.17B$3.55M-11.57400News CoveragePositive NewsUpcoming EarningsTWSTTwist Bioscience3.566 of 5 stars$36.53+1.5%$50.40+38.0%-36.5%$2.16B$312.97M-11.24990News CoverageUpcoming EarningsShort Interest ↑Gap DownHRMYHarmony Biosciences4.7364 of 5 stars$35.76-4.7%$51.00+42.6%+5.1%$2.15B$714.73M13.65200Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Amneal Pharmaceuticals Alternatives ImmunityBio Alternatives Bausch Health Cos Alternatives Apellis Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Agios Pharmaceuticals Alternatives Beam Therapeutics Alternatives Arrowhead Pharmaceuticals Alternatives Twist Bioscience Alternatives Harmony Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGO Stock Alerts